Nanoparticles for cardiovascular imaging and therapeutic delivery, part 1: Compositions and features

Journal of Nuclear Medicine

Volumn 56, Issue 10, 2015, Pages 1469-1475

  Stendahl, John C ^a   Sinusas, Albert J ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cardiovascular disease; Molecular imaging; Nanoparticles; Nuclear imaging; Theranostics

Indexed keywords

DENDRIMER; LIPOPROTEIN; LIPOSOME; METAL NANOPARTICLE; NANOPARTICLE; POLYMER; QUANTUM DOT; RADIOPHARMACEUTICAL AGENT;

ARTICLE; CARDIOVASCULAR DISEASE; CAUSAL ATTRIBUTION; CHEMICAL COMPOSITION; EPIDEMIC; HUMAN; HYDROPHILICITY; LIPOPHILICITY; MAGNETIC FIELD; MICELLE; MORTALITY; NANOEMULSION; NANOPROBE; NANOTECHNOLOGY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PARTICLE SIZE; PHOTOTHERAPY; PRIORITY JOURNAL; SURFACE PROPERTY; CARDIOVASCULAR SYSTEM; DRUG DELIVERY SYSTEM; METABOLISM; MOLECULAR IMAGING; MULTIMODAL IMAGING; PROCEDURES; SCINTISCANNING;

CARDIOVASCULAR SYSTEM; DRUG DELIVERY SYSTEMS; HUMANS; MOLECULAR IMAGING; MULTIMODAL IMAGING; NANOPARTICLES; PARTICLE SIZE; RADIOPHARMACEUTICALS;

EID: 84943179661     PISSN: 01615505     EISSN: 2159662X     Source Type: Journal    
DOI: 10.2967/jnumed.115.160994     Document Type: Article

References (62)

1. Alwan A, Armstrong T, Bettcher D, et al. Global Status Report on Noncommunicable Diseases 2010. Geneva, Switzerland: World Health Organization; 2011.
2. Lukyanov AN, Hartner WC, Torchilin VP. Increased accumulation of PEG-PE micelles in the area of experimental myocardial infarction in rabbits. J Controlled Release. 2004;94:187-193.
3. Urakami T, Kawaguchi AT, Akai S, et al. In vivo distribution of liposome-encapsulated hemoglobin determined by positron emission tomography. Artif Organs. 2009;33:164-168.
4. Hwang H, Kwon J, Oh P-S, et al. Peptide-loaded nanoparticles and radionuclide imaging for individualized treatment of myocardial ischemia. Radiology. 2014;273:160-167.
5. Luehmann HP, Pressly ED, Detering L, et al. PET/CT imaging of chemokine receptor CCR5 in vascular injury model using targeted nanoparticle. J Nucl Med. 2014;55:629-634.
6. Majmudar MD, Yoo J, Keliher EJ, et al. Polymeric nanoparticle PET/MR imaging allows macrophage detection in atherosclerotic plaques. Circ Res. 2013;112:755-761.
7. Liu Y, Pressly ED, Abendschein DR, et al. Targeting angiogenesis using a C-type atrial natriuretic factor-conjugated nanoprobe and PET. J Nucl Med. 2011;52: 1956-1963.
8. Fukukawa K-I, Rossin R, Hagooly A, et al. Synthesis and characterization of core-shell star copolymers for in vivo PET imaging applications. Biomacromolecules. 2008;9:1329-1339.
9. Almutairi A, Rossin R, Shokeen M, et al. Biodegradable dendritic positron-emitting nanoprobes for the noninvasive imaging of angiogenesis. Proc Natl Acad Sci USA. 2009;106:685-690.
10. 64Cu-labeled LyP-1-dendrimer for PET-CT imaging of atherosclerotic plaque. Bioconjug Chem. 2014;25:231-239.
11. Criscione JM, Dobrucki LW, Zhuang ZW, et al. Development and application of a multimodal contrast agent for SPECT/CT hybrid imaging. Bioconjug Chem. 2011;22:1784-1792.
12. Jung C, Kaul MG, Bruns OT, et al. Intraperitoneal injection improves the uptake of nanoparticle-labeled high-density lipoprotein to atherosclerotic plaques compared with intravenous injection: a multimodal imaging study in ApoE knockout mice. Circ Cardiovasc Imaging. 2014;7:303-311.
13. 3 expression. Bioconjug Chem. 2011;22:913-922.
14. Nahrendorf M, Keliher E, Marinelli B, et al. Detection of macrophages in aortic aneurysms by nanoparticle positron emission tomography-computed tomography. Arterioscler Thromb Vasc Biol. 2011;31:750-757.
15. Ueno T, Dutta P, Keliher E, et al. Nanoparticle PET-CT detects rejection and immunomodulation in cardiac allografts. Circ Cardiovasc Imaging. 2013;6: 568-573.
16. 18F labeled nanoparticles for in vivo PET-CT imaging. Bioconjug Chem. 2009;20: 397-401.
17. Lijowski M, Caruthers S, Hu G, et al. High-resolution SPECT-CT/MR molecular imaging of angiogenesis in the Vx2 model. Invest Radiol. 2009;44: 15-22.
18. Liu Z, Cai W, He L, et al. In vivo biodistribution and highly efficient tumour targeting of carbon nanotubes in mice. Nat Nanotechnol. 2007;2:47-52.
19. 31 nanophosphors for upconversion luminescence, MR, and PET imaging of tumor angiogenesis. J Nucl Med. 2013;54:96-103.
20. Mitragotri S, Lahann J. Physical approaches to biomaterial design. Nat Mater. 2009;8:15-23.
21. Ernsting MJ, Murakami M, Roy A, Li SD. Factors controlling the pharmacokinetics, biodistribution and intratumoral penetration of nanoparticles. J Control Release. 2013;172:782-794.
22. Choi HS, Liu W, Misra P, et al. Renal clearance of quantum dots. Nat Biotechnol. 2007;25:1165-1170.
23. 1-containing liposomes. Biochim Biophys Acta. 1992;1104:95-101.
24. Hrkach J, Von Hoff D, Mukkaram Ali M, et al. Preclinical developmental and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile. Sci Transl Med. 2012;4:128ra39.
25. Kiessling F, Mertens ME, Grimm J, Lammers T. Nanoparticles for imaging: top or flop? Radiology. 2014;273:10-28.
26. Choi HS, Liu W, Liu F, et al. Design considerations for tumour-targeted nanoparticles. Nat Nanotechnol. 2010;5:42-47.
27. Rizvi SB, Ghaderi S, Keshtgar M, Seifalian AM. Semiconductor quantum dots as fluorescent probes for in vitro and in vivo bio-molecular and cellular imaging. Nano Rev. 2010;1:5161.
28. Stirrat CG, Newby DE, Robson JMJ, Jansen MA. The use of superparamagnetic iron oxide nanoparticles to assess cardiac inflammation. Curr Cardiovasc Imaging Rep. 2014;7:9263.
29. Jaque D, Martinez Maestro L, del Rosal B, et al. Nanoparticles for photothermal therapies. Nanoscale. 2014;6:9494-9530.
30. Cormode DP, Skajaa T, van Schooneveld MM, et al. Nanocrystal core high-density lipoproteins: a multimodality contrast agent platform. Nano Lett. 2008;8: 3715-3723.
31. Chen IY, Wu JC. Cardiovascular molecular imaging: focus on clinical translation. Circulation. 2011;123:425-443.
32. Winter P, Athey P, Kiefer G, et al. Improved paramagnetic chelate for molecular imaging with MRI. J Magn Magn Mater. 2005;293:540-545.
33. Ragheb RR, Kim D, Bandyopadhyay A, et al. Induced clustered nanoconfinement of superparamagnetic iron oxide in biodegradable nanoparticles enhances transverse relaxivity for targeted theranostics. Magn Reson Med. 2013;70: 1748-1760.
34. 3-targeted paramagnetic nanoparticles. Radiology. 2013;268:470-480.
35. Chen W, Cormode DP, Vengrenyuk Y, et al. Collagen-specific peptide conjugated HDL nanoparticles as MRI contrast agent to evaluate compositional changes in atherosclerotic plaque regression. JACC Cardiovasc Imaging. 2013;6: 373-384.
36. Cheng K, Shen D, Hensley MT, et al. Magnetic antibody-linked nanomatchmakers for therapeutic cell targeting. Nat Commun. 2014;5:4880.
37. Hyafil F, Cornily JC, Feig JE, et al. Noninvasive detection of macrophages using a nanoparticulate contrast agent for computed tomography. Nat Med. 2007;13: 636-641.
38. Winter PM, Shukla HP, Caruthers SD, et al. Molecular imaging of human thrombus with computed tomography. Acad Radiol. 2005;12(suppl): S9-S13.
39. Danila D, Johnson E, Kee P. CT imaging of myocardial scars with collagen-targeting gold nanoparticles. Nanomedicine. 2013;9:1067-1076.
40. Anderson NG, Butler AP. Clinical applications of spectral molecular imaging: potential and challenges. Contrast Media Mol Imaging. 2014;9:3-12.
41. Cormode DP, Roessl E, Thran A, et al. Atherosclerotic plaque composition: analysis with multicolor CT and targeted gold nanoparticles. Radiology. 2010; 256:774-782.
42. Zainon R, Ronaldson JP, Janmale T, et al. Spectral CT of carotid atherosclerotic plaque: comparison with histology. Eur Radiol. 2012;22:2581-2588.
43. Bhavane R, Badea C, Ghaghada KB, et al. Dual-energy computed tomography imaging of atherosclerotic plaques in a mouse model using a liposomal-iodine nanoparticle contrast agent. Circ Cardiovasc Imaging. 2013;6:285-294.
44. Pan D, Schirra CO, Wickline SA, Lanza GM. Multicolor computed tomographic molecular imaging with noncrystalline high-metal-density nanobeacons. Contrast Media Mol Imaging. 2014;9:13-25.
45. Chen F, Ehlerding EB, Cai W. Theranostic nanoparticles. J Nucl Med. 2014;55: 1919-1922.
46. 3 integrin-targeted fumagillin nanoparticles inhibit angiogenesis in atherosclerosis. Arterioscler Thromb Vasc Biol. 2006;26:2103-2109.
47. Lobatto ME, Fayad ZA, Slivera S, et al. Multimodal clinical imaging to longitudinally assess a nanomedical anti-inflammatory treatment in experimental atherosclerosis. Mol Pharm. 2010;7:2020-2029.
48. Duivenvoorden R, Tang J, Cormode DP, et al. A statin-loaded reconstituted high-density lipoprotein nanoparticle inhibits atherosclerotic plaque inflammation. Nat Commun. 2014;5:3065.
49. 3-integrin-targeted nanoparticles. Magn Reson Med. 2010;64:369-376.
50. Fujii H, Li SH, Wu J, et al. Repeated and targeted transfer of angiogenic plasmids into the infarcted rat heart via ultrasound targeted microbubble destruction enhances cardiac repair. Eur Heart J. 2011;32:2075-2084.
51. Harel-Adar T, Ben Mordechai T, Amsalem Y, Feinberg MS, Leor J, Cohen S. Modulation of cardiac macrophages by phosphatidylserine-presenting liposomes improves infarct repair. Proc Natl Acad Sci USA. 2011;108:1827-1832.
52. Leor J, Rozen L, Zuloff-Shani A, et al. Ex vivo activated human macrophages improve healing, remodeling, and function of the infarcted heart. Circulation. 2006;114:I94-I100.
53. Fredman G, Kamaly N, Spolitu S, et al. Targeted nanoparticles containing the proresolving peptide Ac2-26 protect against advanced atherosclerosis in hypercholesteremic mice. Sci Transl Med. 2015;7:275ra20.
54. Katsuki S, Matoba T, Nakashiro S, et al. Nanoparticle-mediated delivery of pitavastatin inhibits atherosclerotic plaque destabilization/rupture in mice by regulating the recruitment of inflammatory monocytes. Circulation. 2014;129: 896-906.
55. Nagahama R, Matoba T, Nakano K, Kim-Mitsuyama S, Sunagawa K, Egashira K. Nanoparticle-mediated delivery of pioglitazone enhances therapeutic neovascularization in a murine model of hindlimb ischemia. Arterioscler Thromb Vasc Biol. 2012;32:2427-2434.
56. Leuschner F, Dutta P, Gorbatov R, et al. Therapeutic siRNA silencing in inflammatory monocytes in mice. Nat Biotechnol. 2011;29:1005-1010.
57. Bartlett DW, Su H, Hildebrandt IJ, Weber WA, Davis ME. Impact of tumor-specific targeting on the biodistribution and efficacy of siRNA nanoparticles measured by multimodality in vivo imaging. Proc Natl Acad Sci USA. 2007; 104:15549-15554.
58. Kirpotin DB, Drummond DC, Shao Y, et al. Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. Cancer Res. 2006;66:6732-6740.
59. Andresen TL, Jensen SS, Jorgensen K. Advanced strategies in liposomal cancer therapy: problems and prospects of active and tumor specific drug release. Prog Lipid Res. 2005;44:68-97.
60. Bulte JW, Schmieder AH, Keupp J, Caruthers SD, Wickline SA, Lanza GM. MR cholangiography demonstrates unsuspected rapid biliary clearance of nanoparticles in rodents: implications for clinical translation. Nanomedicine. 2014;10: 1385-1388.
61. Choi HS, Frangioni JV. Nanoparticles for biomedical imaging: fundamentals of clinical translation. Mol Imaging. 2010;9:291-310.
62. Pan D, Williams TA, Senpan A, et al. Detecting vascular biosignatures with a colloidal, radio-opaque polymeric nanoparticle. J Am Chem Soc. 2009;131: 15522-15527.